Oppenheimer resumed coverage of Centessa (CNTA) with an Outperform rating and $40 price target The firm cites its conviction for lead asset ORX750 to represent best-in-class potential among orexin-2 receptor agonists, with near-term Phase 2a CRYSTAL-1 data in idiopathic hypersomnia and narcolepsy type-1 and -2 expected this year – likely Q4 2025, given ct.gov information. Presentations at World Sleep for other OX2R agonists should inform the competitive bar for ORX750. Oppenheimer believes the market opportunity for ORX750 is substantial.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA:
- Buy Rating on Centessa Pharmaceuticals Driven by Promising Drug Candidates and Strong Financial Position
- Centessa Pharmaceuticals: Buy Rating Driven by ORX750’s Promising Efficacy and Acquisition Potential
- Centessa Pharmaceuticals: Promising Pipeline Developments and Strategic Flexibility Drive Buy Rating
- Centessa Pharmaceuticals Advances Orexin Agonist Pipeline
- Centessa reports Q2 EPS (38c), consensus (35c)